Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort
Catalyst Biosciences announced that its collaborator ISU Abxis has completed dosing of the first subcutaneous cohort in an ongoing Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B. The companies plan to have interim top-line data from the trial by the end of 2017. September 25, 2017